As part of the approval, DermTech will market and sell the pigmented lesions assay in Canada, while samples will be processed at the company's lab in California.
Despite the initial high cost, the firm believes the assay's improved accuracy and sensitivity will sway clinical and payor interest.
Researchers identified rises and declines in disease risk that appeared to coincide with the proportion of ancestry from Mapuche and Aymara populations.
A genome-wide association study and meta-analysis uncovered several possible ties to multiple keratinocyte cancer versus single keratinocyte cancer cases.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.
The study confirmed 17 previously identified loci, and uncovered 14 new ones that researchers hope can improve understanding of BCC pathogenesis and inform strategies for prevention.
An international team has uncovered roles for MYCN, PTPN14, and LATS1 mutations in the development and progression of skin basal cell carcinoma.
An analysis of angiosarcoma-derived cell lines identified a NUP160-SLC43A3 fusion that subsequently turned up in aggressive primary tumor samples.
The startup firm makes a device as an alternative to skin biopsy that can inform PCR- or NGS-based molecular profiling of the sampled region.
The report cited cost and a lack of awareness of such testing among doctors as the main obstacles to greater adoption of MDx testing for cancer patients.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.